SUBSEQUENT EVENTS	6 Months Ended
Jun. 30, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS Divestiture of Ruconest® On August 9, 2016, the Company entered into a definitive agreement to divest all North American commercialization rights to Ruconest® (recombinant human C1 esterase inhibitor) to Pharming Group N.V. ("Pharming"). Under the terms of the agreement, Pharming will pay Valeant aggregate consideration of up to $125 million, including an upfront fee of $60 million payable upon closing and certain sales-based milestone payments of up to $65 million. The transaction is subject to customary closing conditions, in addition to Pharming obtaining certain financing. The carrying values of the assets being sold, including the associated goodwill, were written down to fair value less costs to sell and were classified as assets held for sale, within Prepaids and other current assets in the Consolidated balance sheet, as of June 30, 2016. A loss of $199 million was recorded in Amortization and impairments of finite-lived intangible assets for the three months ended June 30, 2016. Organizational Change On August 9, 2016, the Company announced a new organizational structure which will result in a realignment of the current segment structure. Pursuant to this change, which will become effective in the third quarter of 2016, the Company will have three reportable segments: (i) Bausch + Lomb/International, (ii) Branded Rx, and (iii) U.S. Diversified Products. The Company will commence reporting under this new structure in the third quarter of 2016. Proposed Credit Facility Amendment On August 9, 2016, the Company announced its intention to launch a process to obtain an amendment to our Senior Secured Credit Facilities. Pursuant to the proposed amendment, in order to provide the Company with additional flexibility and to address the limited headroom in its interest coverage ratio maintenance covenant, the Company is seeking to amend the interest coverage maintenance covenant and certain asset sale and debt incurrence baskets that will provide additional flexibility to sell assets and incur debt if the proceeds from either are used to repay term loans. The proposed amendment must be approved by lenders holding more than 50% of the Company’s loans in principal amount. The Company cannot guarantee that the necessary approvals will be obtained.

SUBSEQUENT EVENTS

Divestiture of Ruconest®

On August 9, 2016, the Company entered into a definitive agreement to divest all North American commercialization rights to Ruconest® (recombinant human C1 esterase inhibitor) to Pharming Group N.V. ("Pharming"). Under the terms of the agreement, Pharming will pay Valeant aggregate consideration of up to $125 million, including an upfront fee of $60 million payable upon closing and certain sales-based milestone payments of up to $65 million. The transaction is subject to customary closing conditions, in addition to Pharming obtaining certain financing. The carrying values of the assets being sold, including the associated goodwill, were written down to fair value less costs to sell and were classified as assets held for sale, within Prepaids and other current assets in the Consolidated balance sheet, as of June 30, 2016. A loss of $199 million was recorded in Amortization and impairments of finite-lived intangible assets for the three months ended June 30, 2016.

Organizational Change

On August 9, 2016, the Company announced a new organizational structure which will result in a realignment of the current segment structure. Pursuant to this change, which will become effective in the third quarter of 2016, the Company will have three reportable segments: (i) Bausch + Lomb/International, (ii) Branded Rx, and (iii) U.S. Diversified Products. The Company will commence reporting under this new structure in the third quarter of 2016.

Proposed Credit Facility Amendment

On August 9, 2016, the Company announced its intention to launch a process to obtain an amendment to our Senior Secured Credit Facilities. Pursuant to the proposed amendment, in order to provide the Company with additional flexibility and to address the limited headroom in its interest coverage ratio maintenance covenant, the Company is seeking to amend the interest coverage maintenance covenant and certain asset sale and debt incurrence baskets that will provide additional flexibility to sell assets and incur debt if the proceeds from either are used to repay term loans. The proposed amendment must be approved by lenders holding more than 50% of the Company’s loans in principal amount. The Company cannot guarantee that the necessary approvals will be obtained.